DR. LAURA CASSIDY
Medical College of Wisconsin

CLAIRE EVERS
City of Milwaukee Health Department

MARK GOLDSTEIN
Goldstein Law Group s.c.

Business Strategies
DURING THE PANDEMIC
Tim Sheehy
President
Metro Milwaukee Association of Commerce
As MMAC transitions to our new permanent offices at The Avenue, we want to thank MMAC member Spaces for a much-needed and convenient temporary home at their North Water Street location to host our webinars. With over 3,000 global locations and 10 in Wisconsin, Spaces makes it easy to have a productive day at work. Their all-inclusive, flexible offices and coworking make getting to work easy and affordable.

Additional information: https://www.spacesworks.com/milwaukee/north-water-street/
MKE HEALTH & ECONOMY BRIEFING

On Wisconsin’s Afternoon News
Tuesday @ 4:20pm

John R. Raymond, Sr., MD
Medical College of Wisconsin
President and CEO

Tim Sheehy
MMAC President

620 WTMJ
Wisconsin’s Radio Station

Medical College
of Wisconsin

Metropolitan Milwaukee Association of Commerce
Q. Are you currently willing or unwilling to do each of the following?

<table>
<thead>
<tr>
<th>Activity</th>
<th>May</th>
<th>September</th>
</tr>
</thead>
<tbody>
<tr>
<td>Go grocery shopping</td>
<td>93</td>
<td>94</td>
</tr>
<tr>
<td>Go to a bar</td>
<td>43</td>
<td>34</td>
</tr>
<tr>
<td>Attend a sporting event in a large stadium</td>
<td>36</td>
<td>25</td>
</tr>
<tr>
<td>Go to a gym or health club</td>
<td>51</td>
<td>32</td>
</tr>
<tr>
<td>Stay in a hotel</td>
<td>49</td>
<td>58</td>
</tr>
<tr>
<td>Go to a movie theatre</td>
<td>38</td>
<td>39</td>
</tr>
<tr>
<td>Get a haircut at a barber or salon</td>
<td>71</td>
<td>72</td>
</tr>
<tr>
<td>Attend church</td>
<td>64</td>
<td>55</td>
</tr>
<tr>
<td>Go shopping in a mall</td>
<td>51</td>
<td>55</td>
</tr>
<tr>
<td>Visit friends at their home</td>
<td>69</td>
<td>71</td>
</tr>
<tr>
<td>Visit family at their home</td>
<td>80</td>
<td>81</td>
</tr>
<tr>
<td>Fly on an airplane</td>
<td>42</td>
<td>36</td>
</tr>
<tr>
<td>Go to work</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Eat at a restaurant</td>
<td>45</td>
<td>55</td>
</tr>
<tr>
<td>Send your child to school</td>
<td>49</td>
<td>65</td>
</tr>
</tbody>
</table>

▲ = Significant increased willingness
▼ = Significant decreased willingness
Q. Are you currently willing or unwilling to do each of the following?

Republicans More Willing to Continue Typical Behaviors
COVID-19 Update

John R. Raymond, Sr., MD
President and CEO
Medical College of Wisconsin

Analytics by Andrew Yaspan
MCW Institute for Health and Equity
COVID-19 DIAGNOSTIC TESTING – 09.21.2020

• Cumulative people tested reported as of yesterday: WI = 1,440,125; MKE = 264,321
  - Negative WI 1,337,627 Negative MKE 265,321
  - Positive WI 102,498 Positive MKE 26,900
  - # of people tested reported yesterday in Wisconsin = 6,796
  - Highest single daily total of people tested was 17,410 on 08.04.2020

• Testing capacity: Up to 38,863. 113 laboratories currently testing. 24 planning to test.

• Daily positive tests have been trending very unfavorably in WI over last month
  - Wisconsin = 1,271 (17.4% positivity; 7-day average trending unfavorably)
  - MKE = 113 (21.8% positivity; 7-day average trending very unfavorably)
  - Four of the highest five days occurred between 09.17.2020 and 09.20.2020
  - Previous highest daily positive tests: WI: 2,533 on 09.018.2020; MKE: 477 on 05.29.2020

Learn more at covid19.mcw.edu

09.22.2020
COVID-19 HOSPITAL METRICS – 09.21.2020

• Number of cumulative hospitalizations: 6,692 (6.5% of positive tests - improving)

• Wisconsin hospitalizations on 09.21.2020
  - 433 inpatients - increasing (high was 446 on 04.09.2020; low 235 on 07.04.2020)
  - 131 in ICU – increasing (high was 196 on 04.09.2020; low was 65 on 07.05.2020)
  - Hospitalizations and ICU use are lagging indicators

• ICU capacity: 336 available ICU beds - stable

• Ventilator capacity 1,926 - increased

• PPE trends: Improving (most critical needs = gowns and paper masks)
  - There are concerns about PPE supply chains, but supplies have improved recently
VARIOUS COVID-19 INDICATORS – 09.21.2020

• Recovered: 86,822 (84.7%)  Active: 14,414 (14.1%)  Died: 1,244 (1.2%)

• Death is a **highly lagging indicator**. Wisconsin case fatality rate = 1.2%

• Cumulative deaths:
  - Male: WI = 678 (54.5%)  MKE = 228 (53.9%)
  - Female: WI = 565 (45.4%)  MKE = 195 (46.1%)
  - Black/African American: WI = 230 (18.5%)  MKE = 154 (36.4%)
  - White: WI = 921 (74.0%)  MKE = 186 (44.0%)
  - Hispanic/Latinx: WI = 144 (11.6%)  MKE = 65 (15.4%)
  - **Totals exceed 100% due to overlap between Black/AA and Hispanic/Latin categories**

• Doubling time for positive tests: WI = **45.1 days**  MKE = **83.7 days**

• 7-day growth rate of positive tests: WI = **1.9%** increasing; MKE = **0.7%** increasing

• Reproductive number: WI = **1.29**; MKE = **1.50** (*early indicator*)
We took a troubling turn in Mid-June 40 days > 1.0 MKE Mask Ordinance WI Mask Order Troubling turn

Learn more at covid19.mcw.edu
This log:log plot shows the trajectory of new cases over last seven days vs total cases since 12 March 2020. It gives a visualization of trajectory. Downward is favorable. MKE favorable trend has reversed.

Learn more at covid19.mcw.edu
COVID-19 TRENDS AS OF 09.21.2020

Early indicators are trending unfavorably in Wisconsin

- **R Number**
  - Wisconsin: 1.29
  - Milwaukee: 1.50

- **% Positivity**
  - Wisconsin: 17.4%
  - Milwaukee: 21.8%

7-day average daily new cases

- Wisconsin: 1,791 (Increasing)
- Milwaukee: 192 (Increasing)

Intermediate indicators are stable

- Hospitalizations **increasing**
- Beds **adequate**
- ICU census **increasing**
- ICU rooms **adequate**
- Ventilators **adequate**
- PPE supply **improving**

Lagging indicator

- **Deaths**
  - Wisconsin: **Stable**
  - Milwaukee: **Decreasing slowly**

Learn more at covid19.mcw.edu

Medical College of Wisconsin
Amount of COVID-19 inoculum (infectious dose of virus) is based on four contact parameters: number, proximity, intensity and duration of contacts.
COVID-19 VACCINE TIMELINE – 09.21.2020

• Will we have a COVID-19 vaccine in the US by the end of 2020?
  - Probably, but limited initially to front line healthcare providers, first responders, high risk populations
  - Recruitment has been slowed by deceleration of pandemic in the US
  - No single drug company will be able to meet the short-term demand; many 100’s of million of doses needed

• Will it be safe?
  - Probably, but the time frame has been compressed from average of 12 years to 10-12 months
  - Nine vaccine manufacturers signed a vaccine pledge on 09.08.2020 (next slide)
  - We will not have long term safety data until late 2021
  - Confidence in FDA’s “historic independence as the gold-standard international regulatory body” has been eroded
  - First to market might not be best vaccine

Learn more at covid19.mcw.edu

09.22.2020
COVID-19 VACCINE SAFETY PLEDGE

COVID-19 Vaccine Maker Pledge

We, the undersigned biopharmaceutical companies, want to make clear our ongoing commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles.
COVID-19 VACCINE LEADERS – 09.21.2020

- Pfizer, Biontech: BNT162b2
  - Uses modified mRNA to instruct human ribosomes to build COVID-19 spike protein

- Funding: The companies have decided not to accept US government R&D funding

- Manufacturing and distribution (600+ million doses):
  - 100 million doses to the US government ($1.95 billion purchase)
  - 100 million doses to Canadian government
  - 120 million doses to Japanese government
  - 200-300 million doses to European Union
  - Working on deals with WHO, CEPI and GAVI the Vaccine Alliance

Learn more at covid19.mcw.edu
KEY CRITERIA FOR PFIZER BIONTECH VACCINE TRIAL

• Design: Randomized, observer-blinded, placebo-controlled, stratified
  - Efficacy, safety, immunogenicity

• Vaccine: 2 shots of 30 µg BNT162b2 or placebo administered 21 days apart

• Primary Endpoint: efficacy against symptoms and positive COVID-19 test
  - Secondary endpoint: efficacy against severe COVID-19 (death, shock, ICU, respiratory failure)
  - Results by end of October

• Participants:
  - 21,999 recipients, age 16 and above
  - 40% of participants over 55 years old
  - Randomization to vaccine or placebo at 1:1 ratio

Learn more at covid19.mcw.edu
COVID-19 VACCINE LEADERS – 09.21.2020

- Moderna: mRNA-1273
  - Uses modified mRNA to instruct human ribosomes to build COVID-19 spike protein
- Funding: $2.45 BB (BARDA $955 million + US government $1.525 billion)
- Manufacturing and distribution (1 billion doses):
  - 100 million doses to the US government ($1.525 billion purchase)
  - In discussions with European Commission
  - In discussions with Japanese government
  - Multiple manufacturing deals
    - ROVI, Catalant and CordenPharma

Learn more at covid19.mcw.edu
KEY CRITERIA FOR MODERNA VACCINE TRIAL

- Design: Randomized, stratified, observer-blinded, placebo-controlled
  - Efficacy, safety, immunogenicity
- Vaccine: 2 shots of 100 µg mRNA-1273 or placebo administered 28 days apart
- Primary Endpoint: efficacy to prevent COVID-19, 14 days after second dose; adverse events
  - Secondary endpoint: efficacy to prevent COVID-19 infection and severe COVID-19 infection
  - Results by November
- Participants:
  - 30,000 recipients, age 18 and above
  - 25-40% of participants either over 65 years old, or under 65 with co-morbid risk factors
  - Randomization to vaccine or placebo at 1:1 ratio

Learn more at covid19.mcw.edu
COVID-19 VACCINE LEADERS – 09.21.2020

- **AstraZeneca**: AZD1222
  - Weakened chimpanzee cold virus to deliver genetic material from COVID-19 spike protein

  • Funding: $1.2 billion R&D funding from BARDA
  • Manufacturing and distribution (1.8 billion doses)
    - 300 million dose option to purchase by US government
    - 100 million doses to Great Britain
    - 100 million doses supplied by GAVI and CEPI ($750 million)
    - 1 billion doses supplied by the Serum Institute of India
    - 400 million doses for the European Commission

Learn more at covid19.mcw.edu
KEY CRITERIA FOR ASTRAZENECA VACCINE TRIAL

• Design: Randomized, double-blinded, placebo-controlled
  - Efficacy, safety, immunogenicity
• Vaccine: 2 shots of AZD-1222 (one of two doses) or placebo administered 28 days apart
• Primary Endpoint: efficacy to prevent COVID-19, ≥ 15 days to one year after second dose
  - Secondary endpoints: efficacy and safety up to one year; presence of neutralizing antibodies at 28 days
  - Results by end of 2020
• Participants:
  - Up to 50,000 recipients in US, UK, Brazil, Japan and South Africa, age 18 and above (30,000 in US)
  - Diverse racial, ethnic, geographic groups; who are healthy or have stable co-morbidities
  - Randomization to two different doses of vaccine or placebo at 2:1 ratio
Laura Cassidy, MS, PhD
Professor and Director
Division of Epidemiology
Director, MS Program in Global Health Equity
Medical College of Wisconsin
General Questions about COVID-19 and the Workplace

- How should employer help prevent spread of COVID-19?
- Should employees self-monitor for symptoms prior to workday?
- When and how to disinfect
- Signs to seek emergency medical care
- Difference between close contact and outbreak
- Role of Public Health Department

LEARN MORE AT COVID-19.MCW.EDU
Role of Public Health Department
Steps to take if employee tests positive
Need to notify customers or general public
Cleaning after employee tests positive
Return to work plan for employee after testing positive (with or without symptoms)
Return to work plan for employee with a potential exposure
Risk Index for COVID-19

Regional population density
- Income level
- Education level
- Age (60+)

Population Density Index
- Smoking or vaping
- Diabetes
- Asthma
- Heart conditions

Preconditions Index

Workplace Interactions Index
- Number of workplace social interactions by occupation

Risk Index

Learn more at COVID-19.MCW.EDU
Flu vaccine does not increase risk of, or prevent, COVID-19

Flu vaccine prevents flu – healthier bodies fight COVID-19 better
  • Brazilian and Canadian studies report fewer COVID-19 deaths if individuals received flu vaccine

Flu + COVID-19: body will be weak, have trouble fighting COVID-19

Influenza virus and Coronaviruses are respiratory illnesses
  • COVID-19 has longer term and potentially more severe symptoms

Flu vaccine prevents hospitalizations, reduces burden on healthcare system (Only ~ 40% of Wisconsinites get flu vaccine)

LEARN MORE AT COVID-19.MCW.EDU
Health Department definition of contact exposure:
• being within 6 feet of an infected person for more than 15 minutes in a single day starting 48 hours before illness onset

Close contacts should not come to work until they have quarantined for at least 10 days since last exposure

Clearly communicate policies about time off due to COVID-19 (paid sick leave, possible government assistance programs)
Notify appropriate employer official and local health dept
Isolate employee, ensure they get home and self-quarantine
Disinfect work area
Maintain confidentiality of employee’s identity
In most cases, no need to shut down unless evidence of significant transmission exists
Temporary closure allows for contact tracing, disinfecting and testing
Negative test is no longer required to discontinue isolation

Symptom criteria reduced to “at least 24 hours since last fever without fever-reducing medications” (was “at least 72 hours”)

“Improvement in respiratory symptoms” changed to “improvement in symptoms”

Longer isolation (up to 20 days after symptom onset) may be warranted for severe symptoms

For asymptomatic patients with a positive RT-PCR test for COVID-19, isolation can be discontinued 10 days after test
Claire Evers
Deputy Commissioner of Environmental Health
City of Milwaukee Health Department
THIS IS FINE.
Julia Ioffe @juliaioffe · Sep 15

Last night when I was in the ER, I asked the absolutely wonderful doctor taking care of me if, five weeks into #COVID19, I were still contagious. He said he didn't know, adding, "The CDC has guidelines for this, but I don't trust the CDC anymore."

That's where we are, folks.
POINTS OF CONFUSION

❖ CDC credibility issues
  ❖ Changed relative to testing for close contact exposure (08/24) (test not warranted unless symptomatic);
  ❖ Reversed – if close contact, get tested (09/18);
  ❖ Language re: transmission issued, then disappeared (09/21)
❖ Current CDC guidance
  ❖ Exposure to person who tested positive or symptomatic – **14 day** self-quarantine (irrespective of mask/PPE)
  ❖ If symptomatic, **10 days** after symptom onset (and resolution of fever for 24 hrs. w/o medication and improvement of other symptoms)
    ❖ Previously 72 hrs.
  ❖ If asymptomatic, **10 days** after first positive test
❖ Employers looking to state and local health officials, medical providers
❖ Employers instituting more stringent rules
  ❖ Return to work
  ❖ Off-duty activities, travel
❖ Children, as susceptible and as carriers
OTHER LEGAL CONSIDERATIONS

❖ FFCRA (EPSL & EFML)
❖ PPP/Employee Retention Tax Credit
❖ Social Security tax deferral
❖ Unemployment Insurance
  ❖ LWA (Lost Wage Assistance)
  ❖ Work-Share
❖ OSHA
❖ Worker’s Compensation
❖ Mask Mandates
POINTS OF FRICTION

❖ Return to work
  ❖ Employee reticence
  ❖ Underlying health conditions
  ❖ Anxiety
  ❖ Off-duty conduct
  ❖ Complacency
  ❖ Lines of communication

❖ Working remotely
  ❖ Children
  ❖ Productivity/Communication

❖ FFCRA
  ❖ EPSL
  ❖ EFML
HOW TO PROSPER DURING UNCERTAINTY

Wednesday, October 28, 2020 10:00 AM - 11:30 AM CST

Webinar

How to Prosper During Uncertainty:
Cut through fear & politics by using data to strengthen your business

Presented by the CEOs of Growing Businesses (CGB)

With

Brian Beaulieu
CEO of ITR Economics

Sponsors
coronavirus-MMAC.org

Resources for Milwaukee businesses during the pandemic including:

• Safety & Health Toolkit
• PPE Product Marketplace
• Best practices for operating safely
• Replay our pandemic programming:


Tuesdays @ 11am